Epidermal growth factor receptor inhibitor market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are accelerating the growth of the global epidermal growth factor receptor inhibitor market include growing incidences of cancer globally, along with the increasing geriatric population and lifestyle changes. Epidermal growth factor inhibitors (EGFRI) is the first targeted cancer therapy, which has become an essential treatment for many advanced-stage epithelial cancers. In comparison to conventional chemotherapies, these agents have the superior ability to target cancer cells, further offering a better safety profile to the patients.
Epidermal growth factor receptor (EGFR) inhibitors are medicines that slow down or stop EGFR’s activity, a protein found on the surface of some normal cells, by binding to its certain part. EGFR or epidermal growth factor receptor causes cells to divide upon binding to it by signalling pathways that control cell division and survival, leading to the growth of normal cells. Certain mutations in EGFR are known to be vulnerable and can lead to the growth of cancer cells.
The global epidermal growth factor receptor inhibitor market analysis includes some of the key market players such as Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in April 2021, Takeda announces US FDA grants priority review for a new drug application for Mobocertinib (TAK-788) as a treatment for EGFR Exon20 Insertion+ metastatic non-small cell lung cancer.
To Request a Sample of our Report on Epidermal Growth Factor Receptor Inhibitor Market: https://www.omrglobal.com/request-sample/epidermal-growth-factor-receptor-inhibitor-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape: Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others.
Epidermal Growth Factor Receptor Inhibitor Market by Segment
By Type
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
By Application
- Hospital
- Research Institutes and Institutions
- Clinic
- Other
A full Report of Epidermal Growth Factor Receptor Inhibitor Market is Available at: https://www.omrglobal.com/industry-reports/epidermal-growth-factor-receptor-inhibitor-market
Epidermal Growth Factor Receptor Inhibitor Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
